Summary

After two years of subdued performance, the Indian pharmaceutical sector should see improved growth over the next 18-24 months. The upturn is being supported by improving business environment in the US, steading domestic demand, and more recently, depreciation of the rupee. 

How sustainable is this growth trajectory and how are Indian companies strategising to make use of available opportunities?

CRISIL invites you to its webinar to discuss the emerging business landscape and opportunities for Indian drug makers, where our experts will elaborate on the following:

• Outlook on revenue growth across key segments
• Direction and intensity of regulatory scrutiny by US Food and Drug Administration
• Criticality and challenges in focusing on complex generics for global markets
• Potential impact of recent government initiatives on domestic pharmaceutical revenues
• Profitability indicators and impact on credit profiles

The presentation by CRISIL will be followed by a panel discussion with industry leaders and a Q&A session.